Evoke Pharma announced an agreement with Spaulding Clinical Research for a trial of the company’s lead product Gimoti comparative exposure pharmacokinetic trial.
Mateon Therapeutics announced a set of interim data from its ongoing Phase 2/3 study in patients with platinum-resistant ovarian cancer using CA4P.
Lexaria Bioscience Corporation (CSE:LXX,OTCQB:LXRP) welcomes the newly proposed Canadian legislation designed to allow for adult legal access to Cannabis (the “Cannabis Act”). In line with the Cannabis Act’s objective to protect public health and public safety, powerful demographic and lifestyle forces are trending away from both the harmful effects related
CytRx Corporation leads the list of last week’s life science gainers on the NASDAQ, followed by Rockwell Medical, ImmunoGen, NewLink Genetics and TearLab.
IntelGenx in collaboration with RedHill Biopharma announced the Ministry of Health of Luxembourg has granted national marketing authorization for RIZAPORT, which treats acute migraines.
By Pia Rivera
BioSig Technologies, Inc. (OTCQB: BSGM) announced its Chairman Kenneth L. Londoner will be presenting at the Monaco Growth Forums Spring Edition April 24th at the Mondrian Hotel in London, England, and April 25th – 26th at The Fairmont Hotel in Monte Carlo, Monaco.
Inovio Pharmaceuticals announced its Ebola vaccine showed promising preliminary results from an expanded Phase I study.
Moleculin Biotech announced it appointed Theradex Systems as its contract research organization for the Phase I/II clinical trials for Annamycin.